Do you routinely monitor CEA in addition to CA 19-9 in patients with pancreatic cancer?

Yes. All patients are monitored serially with CEA and CA 19.9. If bilirubin is elevated due to obstruction rather than hepatic metastases, CA 19.9 elevation relates to obstruction rather than cancer status. In patients who do not have elevated CEA or CA 19.9 on presentation, we utilize ctDNA as a ma...